These stocks are all trading near their 52-week lows, but they're all solid investments to hold over the long term.
Compare NVS Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: Novartis
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer.
It was partially because of COVID-19.
The FDA's inability to inspect an overseas manufacturing facility is holding up an application for inclisiran.
Using traditional metrics, it seems in peril, but another calculation may indicate just how safe the payout is.
Congressional Committee Accuses Amgen and Peers of Hiking Drug Prices to Meet "Aggressive" Revenue Targets
A House committee has issued detailed reports about some of their drug price increases.
AstraZenca, GlaxoSmithKline, Novartis and Eli Lilly are using artificial intelligence systems to help in drug development, decision-making, and more.
Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.
The big drugmaker missed analysts' revenue and earnings estimates due to one primary reason.
The move hastens the demise of the malaria drug as a potential treatment for the disease.